Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ferone

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
Clinical Endocrinology|September 1, 1999
Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective studyP Razzore, A Colao, R Baldelli, et al.
The Journal of Clinical Endocrinology and Metabolism|November 30, 2000
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)R Baldelli, A Colao, P Razzore, et al.
Journal of Endocrinological Investigation|July 16, 2011
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard dosesP Ferolla, A Faggiano, F Grimaldi, et al.
Journal of Endocrinological Investigation|April 20, 2017
Erratum to: Long-term safety and efficacy of Omnitrope<sup>®</sup> in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults studyD Ferone, E Profka, V Gasco, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 1997
Effect of octreotide pretreatment on surgical outcome in acromegalyA Colao, D Ferone, P Cappabianca, et al.
Journal of Endocrinological Investigation|February 6, 2017
Long-term safety and efficacy of Omnitrope<sup>®</sup> in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults studyD Ferone, E Profka, V Gasco, et al.
Molecular and Cellular Endocrinology|November 12, 2013
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growthM Ruscica, P Magni, L Steffani, et al.
Journal of Endocrinological Investigation|April 5, 2012
Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogsL E A Wildemberg, L V Neto, D F Costa, et al.
European Journal of Endocrinology|February 23, 2021
Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional studyM Albertelli, E Nazzari, A Dotto, et al.
Journal of Endocrinological Investigation|March 18, 2023
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experienceE Monti, S Gay, M Dono, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
Clinical Endocrinology|September 1, 1999
Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective studyP Razzore, A Colao, R Baldelli, et al.
The Journal of Clinical Endocrinology and Metabolism|November 30, 2000
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)R Baldelli, A Colao, P Razzore, et al.
Journal of Endocrinological Investigation|July 16, 2011
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard dosesP Ferolla, A Faggiano, F Grimaldi, et al.
Journal of Endocrinological Investigation|April 20, 2017
Erratum to: Long-term safety and efficacy of Omnitrope<sup>®</sup> in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults studyD Ferone, E Profka, V Gasco, et al.
The Journal of Clinical Endocrinology and Metabolism|November 5, 1997
Effect of octreotide pretreatment on surgical outcome in acromegalyA Colao, D Ferone, P Cappabianca, et al.
Journal of Endocrinological Investigation|February 6, 2017
Long-term safety and efficacy of Omnitrope<sup>®</sup> in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults studyD Ferone, E Profka, V Gasco, et al.
Molecular and Cellular Endocrinology|November 12, 2013
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growthM Ruscica, P Magni, L Steffani, et al.
Journal of Endocrinological Investigation|April 5, 2012
Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogsL E A Wildemberg, L V Neto, D F Costa, et al.
European Journal of Endocrinology|February 23, 2021
Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional studyM Albertelli, E Nazzari, A Dotto, et al.
Journal of Endocrinological Investigation|March 18, 2023
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experienceE Monti, S Gay, M Dono, et al.
Pageof 14